Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.
choline PET/TC
metabolic activity
metastatic castration-resistant prostate cancer
plasma tumour DNA
prognosis
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
01
09
2021
received:
11
06
2021
accepted:
15
10
2021
pubmed:
18
10
2021
medline:
2
4
2022
entrez:
17
10
2021
Statut:
ppublish
Résumé
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and better predict treatment outcome in combination with functional imaging. Targeted next-generation sequencing was performed to estimate the ptDNA fraction from 102 mCRPC patients receiving abiraterone or enzalutamide. The maximum standardized uptake value (SUVmax), total lesion activity (TLA) and metabolic tumour volume (MTV) were evaluated on
Identifiants
pubmed: 34657387
doi: 10.1002/1878-0261.13120
pmc: PMC8763654
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
538-548Informations de copyright
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
Ann Oncol. 2016 Mar;27(3):454-60
pubmed: 26685010
Clin Genitourin Cancer. 2017 Jul 25;:
pubmed: 28844792
Oncotarget. 2014 Dec 15;5(23):12448-58
pubmed: 25504434
J Clin Oncol. 2003 Apr 1;21(7):1232-7
pubmed: 12663709
J Clin Oncol. 2020 Nov 1;38(31):3662-3671
pubmed: 32897830
Cells. 2021 Jan 19;10(1):
pubmed: 33478015
J Clin Invest. 2020 Apr 1;130(4):1653-1668
pubmed: 32091413
Clin Cancer Res. 2007 Nov 1;13(21):6396-403
pubmed: 17975152
Eur Urol Focus. 2019 Mar;5(2):147-154
pubmed: 30772358
Clin Cancer Res. 2021 Aug 15;27(16):4610-4623
pubmed: 34083234
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
J Nucl Med. 2004 Oct;45(10):1734-42
pubmed: 15471842
Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758
pubmed: 29192364
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):705-713
pubmed: 32203070
Ann Oncol. 2018 Nov 1;29(11):2200-2207
pubmed: 30202945
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Radiol Med. 2018 Dec;123(12):952-965
pubmed: 30116970
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83
pubmed: 25808631
J Clin Oncol. 2002 Oct 1;20(19):3972-82
pubmed: 12351594
Prostate Cancer Prostatic Dis. 2019 May;22(2):195-205
pubmed: 30413805
Ann Oncol. 2017 Jul 01;28(7):1508-1516
pubmed: 28472366
Sci Rep. 2017 Nov 14;7(1):15541
pubmed: 29138500
JCO Precis Oncol. 2019 Dec;3:1-13
pubmed: 35100689
Br J Cancer. 2020 Sep;123(6):982-987
pubmed: 32669676
Clin Cancer Res. 2019 Mar 15;25(6):1766-1773
pubmed: 30209161
Urol Oncol. 2020 Jun;38(6):600.e9-600.e15
pubmed: 31953003
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
JAMA Oncol. 2016 Dec 01;2(12):1598-1606
pubmed: 27148695
J Natl Cancer Inst. 2017 Dec 01;109(12):
pubmed: 29206995
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258